Gold prices bounce off 3-week lows; demand likely longer term
Christopher Gibson, the Chief Executive Officer of Recursion Pharmaceuticals , Inc. (NASDAQ:RXRX), recently sold a significant portion of his holdings in the company. According to a regulatory filing, Gibson sold 138,574 shares of Class A Common Stock on March 27, 2025, at a price of $6.04 per share, totaling approximately $836,986. The sale comes as the stock trades near its 52-week low of $5.60, having declined over 40% in the past year. InvestingPro analysis shows the company maintains a weak financial health score of 1.69 out of 5. Following this transaction, Gibson retains direct ownership of 1,117,450 shares of Class A Common Stock. The sale was conducted under a Rule 10b5-1 trading plan adopted by Gibson in December 2024. While the company holds more cash than debt on its balance sheet, three analysts have recently revised their earnings estimates downward. Get access to 10+ additional InvestingPro insights and comprehensive analysis in our Pro Research Report.
In other recent news, Recursion Pharmaceuticals reported fourth-quarter revenues of $4.5 million, which fell short of analyst expectations and Cowen’s projection of $19 million. The company posted a loss of $0.53 per share, wider than the anticipated $0.41 loss. For the full year 2024, Recursion generated revenue of $58.8 million, an increase from $44.6 million in 2023, largely due to a $30 million payment from Roche and Genentech. Despite missing quarterly estimates, Recursion highlighted promising early efficacy data for clinical programs like REC-617 for solid tumors and REC-994 for cerebral cavernous malformations.
The company also initiated three new clinical studies across oncology, rare disease, and recurrent C. difficile infection. Recursion ended the year with $603 million in cash and equivalents, up from $401.4 million at the end of 2023, and expects its cash runway to extend into 2027. In terms of strategic moves, the company is focused on realizing over $100 million in cost synergies from its merger with EXAI, with most benefits anticipated by 2025. Analyst Brendan Smith from TD Cowen maintained a Hold rating on Recursion, noting the significance of the merger synergies and upcoming data from key drug trials. Despite the shortfall in revenue and increased operating expenses, Recursion continues to advance its AI-powered drug discovery platform and expand its clinical pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.